Maxim Group downgraded shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) from a buy rating to a hold rating in a report issued on Wednesday morning, Marketbeat reports.
Separately, StockNews.com assumed coverage on Moleculin Biotech in a research note on Sunday. They set a “sell” rating on the stock.
View Our Latest Analysis on Moleculin Biotech
Moleculin Biotech Stock Down 17.2 %
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Read More
- Five stocks we like better than Moleculin Biotech
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Digital Turbine Roars Back—What’s Driving the Ad Tech Surge?
- How to Calculate Return on Investment (ROI)
- 6 Stocks Poised to Benefit From a Trade War in Unexpected Ways
- What Are Dividend Achievers? An Introduction
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
